Viheal Pharma Resubmits Hong Kong IPO Application on June 25, Backed by Huatai International

According to Hong Kong Exchanges and Clearing disclosure on June 25, Viheal International Holdings Group Limited (Viheal Pharma) submitted its IPO application to the Hong Kong Main Board, marking the company's second submission. Huatai International serves as the sole sponsor. The company had previously filed its initial IPO application on November 7, 2025. Viheal Pharma specializes in comprehensive pharmaceutical solutions for kidney disease treatment.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments